WT1 and plasma cell myeloma: In the phase I clinical trial, autologous Langerhans-type DCs were electroporated with mRNA molecules encoding Cancer testis antigen 7 (CT7), Melanoma-associated antigen (MAGE) A3, and Wilms tumor 1 (WT1) and administered intradermally into patients with multiple myeloma following ASCT.